Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

2Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Published 12 September 2022
Categorized as 2022, Invir.IO, Press release, TG6002

Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022

2022 Half-year results and business update

Published 7 September 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene announces Upcoming Investor Meetings

Transgene announces upcoming investor meetings

Published 31 August 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®

Transgene and bioinvent announce clinical collaboration

Published 28 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Transgene and BioInvent announce positive progress for BT-001

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 27 June 2022
Categorized as 2022, 2022, BT-001, Press release, Invir.IO, Invir.IO, Press release

Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022

Transgene presented additional Phase I Data with TG4050 at ASCO 2022

Published 6 June 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022

Transgene to present updated positive preliminary data at ASCO 2022

Published 27 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Myvac, Press release, TG4050

Transgene’s Combined General Meeting of May 25, 2022

Transgene’s combined general meeting of May 25, 2022

Published 25 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Transgene Announces Upcoming Investor Meetings

Transgene annonces upcoming investor meetings

Published 17 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022

All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022

Published 10 May 2022
Categorized as 2022, 2022, Press release, Invir.IO, Press release

Posts pagination

Newer posts Page 1 … Page 12 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu